Payment overview · 2025
General Payments
$43.03
3 reported records · 3 companies
Healthcare provider profile · identity verified
Kimberly E Russell, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GREENWOOD, SC · NPI 1548226962
Verified facts
What the public records show
CMS Open Payments records show Kimberly E Russell, M.D. received $43.03 in general payments during 2025 across 3 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 34.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.99 | 34.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.09 | 32.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.95 | 32.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $43.03 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
114 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 636 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 436 | 113 |
| Losartan Potassium | Losartan Potassium | 396 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 391 | 103 |
| Lisinopril | Lisinopril | 338 | 93 |
| Omeprazole | Omeprazole | 336 | 94 |
| Potassium Chloride | Potassium Chloride | 307 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 263 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 230 | 64 |
| Furosemide | Furosemide | 210 | 63 |
| Gabapentin | Gabapentin | 203 | 54 |
| Metformin Hcl | Metformin Hcl | 192 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 61 |
| Pravastatin Sodium | Pravastatin Sodium | 180 | 48 |
| Simvastatin | Simvastatin | 171 | 47 |
| Alprazolam | Alprazolam | 164 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 161 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 32 |
| Lorazepam | Lorazepam | 155 | 35 |
| Famotidine | Famotidine | 153 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 153 | 28 |
| Montelukast Sodium | Montelukast Sodium | 151 | 40 |
| Glimepiride | Glimepiride | 149 | 37 |
| Trazodone Hcl | Trazodone Hcl | 146 | 28 |
| Sertraline Hcl | Sertraline Hcl | 133 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 129 | 23 |
| Meloxicam | Meloxicam | 127 | 33 |
| Synthroid | Levothyroxine Sodium | 114 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 29 |
| Carvedilol | Carvedilol | 110 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 30 |
| Metformin Hcl Er | Metformin Hcl | 100 | 22 |
| Donepezil Hcl | Donepezil Hcl | 99 | 26 |
| Eliquis | Apixaban | 94 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 20 |
| Tramadol Hcl | Tramadol Hcl | 87 | 30 |
| Mirtazapine | Mirtazapine | 84 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 20 |
| Allopurinol | Allopurinol | 78 | 20 |
| Buspirone Hcl | Buspirone Hcl | 78 | 16 |
| Estradiol | Estradiol | 75 | 20 |
| Bupropion Xl | Bupropion Hcl | 70 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 68 | 16 |
| Atenolol | Atenolol | 66 | 22 |
| Celecoxib | Celecoxib | 66 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 61 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 12 |
| Memantine Hcl | Memantine Hcl | 49 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 12 |
| Spironolactone | Spironolactone | 47 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 38 |
| Pregabalin | Pregabalin | 44 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | 12 |
| Diazepam | Diazepam | 38 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 38 | 32 |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 24 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 28 |
| Meclizine Hcl | Meclizine Hcl | 31 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 14 |
| Prednisone | Prednisone | 30 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 21 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Celebrex | Celecoxib | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $43.03 · 3 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | Dexcom G6 Transmitter, UBRELVY, XIFAXAN | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error